Post by PARI

In drug–device development, teams often face the same challenge: human factors (HF) programs slow down, since the extensive HF knowledge generated for platform nebulizers through various partnerships is considered proprietary data. The result? Repeated testing, rising costs, and unnecessary regulatory risk. ❓So how can pharma and biotech teams accelerate progress while maintaining compliance? 💡In their poster “From Continuity to Competitive Edge – How Long‑Term Collaboration Drives Faster, Frictionless HF Program Success” Simon Buchner and Gavin Moore show that long-term collaboration between HF consultancy and device manufacturer is a true competitive advantage in HF programs. Drawing on years of partnership between PDD and PARI, they demonstrate how embedded learnings streamline HF studies without touching data that is locked within other programs. Integrating proven testing strategies, robust labeling, and platform-wide risk mitigations leads to reduced rework, shortened timelines, and a confident move towards summative testing.  ▶️ Continuity isn’t just operational efficiency. It’s a strategic lever for faster, smoother HF success. 🔗 Find more information on this topic here: https://lnkd.in/d9HVckbP 👉 We are happy to talk about your development project: Email our BD team on [email protected]. #inhalation #respiratory #drugdelivery #pharmapartnering #PharmaInnovation #Biotech #HumanFactorsEngineering #HumanFactors #Usability #PatientSafety